Data from up to 42 months of treatment reinforce lucerastat’s potential as a first-in-class oral substrate reduction therapy addressing key unmet needs across the Fabry populationThe company is ...
A new in vivo pharmacokinetic recall study involving 114 participants in the Estonian Biobank has provided the first clinical ...
The immune system must maintain a delicate balance to defend against harmful threats while avoiding excessive inflammation.
AZoLifeSciences on MSN
Understanding the complex biosynthetic pathway of O-mannose glycans in the brain
Gifu University scientists have uncovered how a brain-specific enzyme reshapes protein-linked sugar chains to facilitate the ...
REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its ...
Gifu University scientists have uncovered how a brain-specific enzyme reshapes protein-linked sugar chains to facilitate the formation of complex glycans essential for normal brain function.
JCR Pharmaceuticals announced that it will present data at the 22nd Annual WORLDSymposium 2026, held February 2-6, 2026, in San Diego, Calif.
Gifu University scientists have uncovered how a brain-specific enzyme reshapes protein-linked sugar chains to facilitate the ...
Raw materials play a critical role in cell therapy manufacturing. Choosing suboptimal materials at any stage of development ...
AZoLifeSciences on MSN
Single enzyme enables low-cost synthesis of all RNA nucleotides
A single enzyme that can generate all four nucleotide triphosphates, the building blocks of ribonucleic acid (RNA), was ...
Researchers identified a polyphosphate kinase that converts nucleotide precursors into all four RNA nucleotides in one step. Using inexpensive polyphosphate, the enzyme enables low-cost, efficient NTP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results